Lv1
90 积分 2025-10-06 加入
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
13小时前
待确认
Pembrolizumab for Early Triple-Negative Breast Cancer
21小时前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
21小时前
已完结
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial
13天前
已完结
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
21天前
已完结
Plasma and serum concentrations of VEGF-A121, but not of VEGF-A165, increase post-bevacizumab administration
24天前
已完结
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
24天前
已完结
Targeting angiogenesis in oncology, ophthalmology and beyond
24天前
已完结
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
24天前
已完结
Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer
2个月前
已完结
皖公网安备34019202002308
